Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00176_DB00395> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00176_DB00395 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB00395 label "DDI between Fluvoxamine and Carisoprodol - Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased. [drugbank_resource:DB00176_DB00395]" assertion.
- drugbank_resource:DB00176_DB00395 identifier "drugbank_resource:DB00176_DB00395" assertion.
- drugbank_resource:DB00176_DB00395 title "DDI between Fluvoxamine and Carisoprodol - Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased." assertion.